Analysts' Actions: AMD, EXPE, FDX, WAB

NEW YORK (TheStreet) -- CHANGE IN RATINGS



Abiomed (ABMD) was downgraded to Hold at TheStreet Ratings.

Advanced Micro Devices (AMD) was downgraded at UBS to Neutral from Buy with a $4 price target. Lower outlook on structural and competitive challenges.

Aeropostale (ARO) upgraded from Neutral to Buy at Bank of America/Merrill Lynch said. $18 price target. Risk/reward is more attractive following the recent selloff.

CGI Group (GIB) was upgraded to Buy at TheStreet Ratings.

Cliffs Natural (CLF) was downgraded at Credit Suisse from Neutral to Underperform. $30 price target. Company is leveraged to the dramatic fall in iron ore prices.

Cornerstone OnDemand (CSOD) was initiated with a Neutral rating, UBS said. $28 price target. High valuation and expectations.

Expedia (EXPE) was downgraded to Hold from Buy at Jefferies. $56 price target. Solid progress as new platform ramps up.

FedEx (FDX) was downgraded from Outperform to Market Perform at Wells Fargo. Estimates also cut, given weakness at Express.

Guess (GES) was downgraded to Hold at TheStreet Ratings.

HSN (HSNI) was downgraded from Buy to Hold at Wunderlich. $50 price target. Valuation call, based on macro growth concerns.

Hartford Financial Services (HIG) was downgraded to Hold by TheStreet Ratings.

Eli Lilly (LLY) was upgraded from Market Perform to Outperform, Bernstein said. $52 price target. Company has a solid late-stage pipeline and there's a better chance that solanezumab is approved for Alzheimer's.

LinkedIn (LNKD) was upgraded to Buy from Hold at Jeffries. $142 price target. Best play in online recruiting.

Louisiana-Pacific (LPX) was downgraded from Hold to Reduce at TD Securities. Valuation call, based on $12.50 price target.

McKesson (MCK) was upgraded from Neutral to Buy at Mizuho. $99 price target. Recent selloff appears overdone.

Qlik Technologies (QLIK) was upgraded from Equal-weight to Overweight at Morgan Stanley said. $28 price target. Recent survey suggests that demand could remain strong for the next two years.

Time Warner (TWX) was upgraded to Buy from Neutral at UBS. $50 price target. Better stability/visibility to EPS.

ViroPharma (VPHM) was initiated with a Buy rating at Deutsche Bank. $37 price target. HAE drug should be the company's main profit growth driver.

Vitamin Shoppe (VSI) was upgraded from Neutral to Buy at Bank of America/Merrill Lynch. $67 price target. Company can sustain healthy growth.

Westinghouse (WAB) was started with an Outperform rating at Credit Suisse. $99 price target. Company has multiple potential growth levers.

Williams-Sonoma (WSM) was upgraded from Hold to Buy at Deutsche Bank. $48 price target. Consistent sales growth is leading to higher margins.

STOCK COMMENTS / EPS CHANGES

Apple (AAPL) target boosted at JP Morgan. Shares of AAPL now seen reaching $770, according to JP Morgan. iPhone and iPad can continue to grow ahead of expectations. Overweight rating.

Amazon (AMZN) numbers raised at Jefferies. Shares of AMZN now seen reaching $300, Jefferies said. Estimates also raised on superior growth. Buy rating.

Campbell Soup (CPB) numbers raised at UBS. Shares of CPB now seen reaching $36, UBS said. Estimates also raised on higher medium term revenue trends. Neutral rating.

eBay (EBAY) numbers raised at Jefferies. Shares of EBAY now seen reaching $56, Jefferies said. Estimates also raised on turnaround in core biz and upside from PayPal. Buy rating.

FedEx (FDX) numbers cut at UBS. Shares of FDX now seen reaching $110, UBS said. Estimates also lowered on weak Express revenue growth. Buy rating.

Finisar (FNSR) numbers lowered at Citigroup. Shares of FNSR now seen reaching $17, Citigroup said. Estimates also lowered on soft guidance. Buy rating.

Francesca's (FRAN) estimates, target raised at Keybanc. Shares of FRAN now seen reaching $38, according to Keybanc. Estimates also increased, as higher sales are driving margin expansion. Buy rating.

Halliburton (HAL) estimates, target cut at SocGen. HAL estimates were reduced through 2014, Societe Generale said. Company is seeing slower drilling activity in North America. Buy rating and new $50 price target.

J.C. Penny (JCP) estimates lowered at Oppenheimer. JCP estimates lowered through 2013, Oppenheimer said. Turnaround continues to take shape. Outperform rating.

This article was written by a staff member of TheStreet.